Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 20Ovarian Neoplasms 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1HR+/HER2- Advanced Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1Advanced Breast Cancer 1

Interventions

apatinib 3vistusertib 2olaparib 2camrelizumab 2atezolizumab 2Ipilimumab 2Everolimus 2trametinib 1toripalimab 1tilsotolimod 1tazemetostat 1tazarotene 1spartalizumab 1seviteronel 1sargramostim 1sacituzumab govitecan 1rucaparib 1roniciclib 1romiplostim 1pyrotinib 1phosphorylethanolamine 1pemigatinib 1pembrolizumab 1pazopanib 1palbociclib 1niraparib 1magrolimab 1lenvatinib 1irinotecan sucrosofate 1famitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumor × dalpiciclib × Clear all
NCT05512780 2022-08-23

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage â…¡-â…¢ HR-positive/HER2-negative Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2 Unknown
30 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡